Also found in: Medical.
MSAFPMaternal Serum Alpha-Fetoprotein
MSAFPMaternal Serum Alpha Fetoprotein Screening (American Pregnancy Association)
References in periodicals archive ?
The best way to approach this question may be to ask what would be a viable cause of a lawsuit concerning MSAFP screening.
The risk of Down's syndrome when the MSAFP is low, or of neural tube defect or anterior abdominal wall defect when the MS-AFP is elevated, is not immediately apparent from unmanipulated data.
In California, where mandatory offering of MSAFP screening has been in effect since the spring of 1986, or about 50 percent of all pregnancies have actually been screened during the second trimester.
An association between low MSAFP and fetal chromosomal abnormalities.
With notice to increase the embryo's age and its size, the amount of AFP that free is increase, so when we measure the MSAFP we, have to determine the embryo's age.
SKM'li hastalarda da diger spinal disrafizm tiplerinde oldugu gibi artmis maternal serum alfafetoprotein (MSAFP) duzeyleri gorulur.
Blood samples (2 ml of EDTA blood from NESTROF test and 3 ml of non-ox lood for MSAFP) were collected from a subgroup of women with known last menstrual period (LMP) between 13-16 wk of gestation for estimation of maternal serum alpha-foetoprotein (MSAFP) and NESTROFT test (Naked Eye Single Tube Osmotic Fragility Test) along with routine haemogram.
Patient's claim The physician failed to communicate the importance of 1) taking folic acid to prevent birth defects and 2) maternal serum [alpha]-fetoprotein (MSAFP) testing to determine if spina bifida was present.
Eligibility criteria included screening for maternal serum alpha-fetoprotein (MSAFP) levels between 15 and 22 weeks of pregnancy, > 14 years of age, competency in English, singleton pregnancy with no known congenital or chromosomal anomalies at the time of recruitment, and no prepregnancy diabetes mellitus.
For example, a patient might ask her physician what the physician would do, given the physician's own values, when faced with the option of an MSAFP test.
Devore (13) estimated that the cost per anomaly detected by sonography was not greater than with routine use of maternal serum alpha-feto protein (MSAFP).
About 30 years ago, elevated alpha fetoprotein (AFP) levels in maternal serum and in amniotic fluid were first linked to the occurrence of fetal NTDs.(10) In 1977, findings of a large collaborative study in the United Kingdom confirmed the value of measuring maternal serum AFP (MSAFP) in screening for NTDs.(11) Prior to that, unless a woman or a close female relative had had a previous NTD-affected pregnancy, there was essentially no way to predict how likely she was to be carrying an NTD-affected fetus.